Bank Of America Corp Humanigen, Inc Transaction History

Bank Of America Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.13 - $0.2 $0 - $0	1 Added 0.01%	13,836 $2,000
Q1 2023 May 12, 2023	SELL	$0.12 - $0.23 $986 - $1,890	-8,218 Reduced 37.26%	13,835 $1,000
Q4 2022 Feb 10, 2023	BUY	$0.09 - $0.2 $739 - $1,643	8,216 Added 59.38%	22,053 $2,000
Q3 2022 Nov 14, 2022	SELL	$0.15 - $3.02 $15,094 - $303,896	-100,628 Reduced 87.91%	13,837 $3,000
Q2 2022 Aug 12, 2022	SELL	$1.76 - $3.33 $376,532 - $712,416	-213,939 Reduced 65.15%	114,465 $202,000
Q1 2022 May 16, 2022	BUY	$1.81 - $3.97 $430,314 - $943,839	237,743 Added 262.23%	328,404 $988,000
Q4 2021 Feb 08, 2022	BUY	$3.66 - $8.22 $238,119 - $534,793	65,060 Added 254.13%	90,661 $337,000
Q3 2021 Nov 15, 2021	SELL	$5.93 - $17.83 $38,711 - $116,394	-6,528 Reduced 20.32%	25,601 $152,000
Q2 2021 Sep 13, 2021	BUY	$13.54 - $22.74 $435,026 - $730,613	32,129 New	32,129 $558,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.